Identifying New Genetic Targets and Therapies for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction

What this Trial Is About

Researchers are studying colorectal cancer CRC, endometrial cancer EC, and hereditary cancer syndromes to better understand genetic predispositions and new treatment possibilities. The study focuses on discovering new mechanisms in intestinal cancer development, identifying genes and proteins for targeted therapies, and exploring how the immune system can recognize and eliminate tumor cells. It aims to create a valuable resource for future research on hereditary and sporadic cancer cases. Participants provide tissue, blood, and clinical data collected during routine clinical care procedures such as gastrointestinal endoscopies, surgeries, transvaginal ultrasounds, hysteroscopies, and endometrial biopsies. Samples include normal mucosa, polyps, tumors, and blood used for molecular and genetic studies. Organoids derived from these tissues will be used to assess drug sensitivity and study cancer biology. During the study, participants clinical data, family history, and biospecimens are collected and stored for future research. Data includes demographics, medical history, treatment details, and outcomes from standard care. This observational study does not involve experimental treatments but contributes to a hereditary cancer registry and tissue repository. The study plans to continue follow-up until 2027, assessing novel genetic mechanisms and immune responses over seven years.

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction